Clinical Trial Update: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 177Lu-DOTA0-Tyr3-Octreotate with Octreotide LAR in inoperable, progressive somatostatin receptor–positive midgut carcinoid tumors comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor of the Small Bowel
• Neuroendocrine Tumor

Drugs mentioned

• 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTA0-Tyr3-Octreotate)
• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour | Phase 3 | Status: COMPLETED | Results posted: 2017-10-02